Biomm SA
BOVESPA:BIOM3

Watchlist Manager
Biomm SA Logo
Biomm SA
BOVESPA:BIOM3
Watchlist
Price: 8.79 BRL -2.66% Market Closed
Market Cap: 1.1B BRL
Have any thoughts about
Biomm SA?
Write Note

Operating Margin
Biomm SA

-62%
Current
-67%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-62%
=
Operating Profit
-76.7m
/
Revenue
123.8m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
BR
Biomm SA
BOVESPA:BIOM3
1.1B BRL
-62%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
312.7B USD
28%
US
Amgen Inc
NASDAQ:AMGN
158.3B USD
19%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.2B USD
40%
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
133.6B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.3B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.8B EUR
-22%
Country BR
Market Cap 1.1B BRL
Operating Margin
-62%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 312.7B USD
Operating Margin
28%
Country US
Market Cap 158.3B USD
Operating Margin
19%
Country US
Market Cap 116.2B USD
Operating Margin
40%
Country US
Market Cap 112.4B USD
Operating Margin
38%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 133.6B AUD
Operating Margin
26%
Country US
Market Cap 81.3B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 34.8B EUR
Operating Margin
-22%
No Stocks Found

Biomm SA
Glance View

Market Cap
1.1B BRL
Industry
Biotechnology

BIOMM SA engages in the research, development, and manufacture of insulin. The company is headquartered in Nova Lima, Minas Gerais. The company went IPO on 2002-09-05. The firm is principally engaged in the development and licensing of technology for the production of human insulin and other recombinant proteins. The Company’s technology is suitable for the production of therapeutic proteins, which are used in the production of drugs and biopharmaceuticals. The Company’s technology for insulin production is protected by patents in various countries in Europe, Asia, North and South America. In addition, it is active in the development of production process of enzymes that are used in the hydrolysis of biomass and in the manufacture of bio-fuel. As of December 31, 2011, the Company’s subsidiaries were Biomm International Inc, Biomm Middle East Inc and Biomm Russia Ltd.

BIOM3 Intrinsic Value
5.32 BRL
Overvaluation 39%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-62%
=
Operating Profit
-76.7m
/
Revenue
123.8m
What is the Operating Margin of Biomm SA?

Based on Biomm SA's most recent financial statements, the company has Operating Margin of -62%.